Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02186119 · ClinicalTrials.gov registry record · Phase 2
A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT02186119 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 151 participants.
The verdict
NCT02186119, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.
Interventions
- DRUG ranibizumab
- DRUG abicipar pegol
- OTHER sham procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02186119
The ClinicalTrials.gov registry entry for NCT02186119 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ranibizumab is the first listed.
NCT02186119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02186119 about?
NCT02186119 is a clinical study titled "A Study of Abicipar Pegol in Patients With Diabetic Macular Edema". This is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.
What is the current status of trial NCT02186119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2014-07. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02186119?
The interventions under investigation include: ranibizumab (DRUG), abicipar pegol (DRUG), sham procedure (OTHER).
Who is sponsoring clinical trial NCT02186119?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.